-
公开(公告)号：US20100098692A1
公开(公告)日：2010-04-22
申请号：US12570918
申请日：2009-09-30
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , A61P27/02 , A61P35/00
CPC分类号： G06Q30/02 , G06Q30/0269
摘要： The present application relates to compositions of humanized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the use of humanized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
摘要翻译： 本申请涉及人源化抗内皮蛋白抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及结合内皮糖蛋白并抑制血管发生的抗体。 另一方面涉及结合内皮糖蛋白用于检测，诊断或治疗与内皮糖蛋白相关的疾病或病症，血管发生或其组合的人源化抗体的用途。
-
公开(公告)号：US08609094B2
公开(公告)日：2013-12-17
申请号：US13485702
申请日：2012-05-31
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/44 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K16/2863 , C07K16/2896 , C07K16/3015 , C07K16/3038 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , G01N33/57492 , G01N33/57496 , G01N33/6872 , G01N2333/70596 , G01N2333/71 , G01N2800/16 , G01N2800/164
摘要： The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
-
公开(公告)号：US20120294864A1
公开(公告)日：2012-11-22
申请号：US13485702
申请日：2012-05-31
IPC分类号： C07K16/18 , A61K39/44 , C12Q1/68 , A61P35/04 , A61P27/02 , A61P19/02 , A61P35/00 , A61K39/395 , C07H21/04
CPC分类号： C07K16/30 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/44 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K16/2863 , C07K16/2896 , C07K16/3015 , C07K16/3038 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , G01N33/57492 , G01N33/57496 , G01N33/6872 , G01N2333/70596 , G01N2333/71 , G01N2800/16 , G01N2800/164
摘要： The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
摘要翻译： 本申请涉及人源化和人源化/去免疫化抗内皮糖蛋白抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及结合内皮糖蛋白并抑制血管发生的抗体。 另一方面涉及人源化抗体的去免疫化以降低免疫原性。 另一方面涉及使用结合内皮糖蛋白的人源化和人源化/去免疫化抗体用于检测，诊断或治疗与内皮因子相关的疾病或病症，血管生成或其组合。
-
公开(公告)号：US08221753B2
公开(公告)日：2012-07-17
申请号：US12751907
申请日：2010-03-31
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C07K16/18
CPC分类号： C07K16/30 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/44 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K16/2863 , C07K16/2896 , C07K16/3015 , C07K16/3038 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , G01N33/57492 , G01N33/57496 , G01N33/6872 , G01N2333/70596 , G01N2333/71 , G01N2800/16 , G01N2800/164
摘要： The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
摘要翻译： 本申请涉及人源化和人源化/去免疫化抗内皮糖蛋白抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及结合内皮糖蛋白并抑制血管发生的抗体。 另一方面涉及人源化抗体的去免疫化以降低免疫原性。 另一方面涉及使用结合内皮糖蛋白的人源化和人源化/去免疫化抗体用于检测，诊断或治疗与内皮因子相关的疾病或病症，血管生成或其组合。
-
公开(公告)号：US20110076263A1
公开(公告)日：2011-03-31
申请号：US12751907
申请日：2010-03-31
IPC分类号： A61K39/395 , C12Q1/68 , C07K16/18 , C07H21/04
CPC分类号： C07K16/30 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/44 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K16/2863 , C07K16/2896 , C07K16/3015 , C07K16/3038 , C07K16/3046 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , G01N33/57492 , G01N33/57496 , G01N33/6872 , G01N2333/70596 , G01N2333/71 , G01N2800/16 , G01N2800/164
摘要： The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
摘要翻译： 本申请涉及人源化和人源化/去免疫化抗内皮糖蛋白抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及结合内皮糖蛋白并抑制血管发生的抗体。 另一方面涉及人源化抗体的去免疫化以降低免疫原性。 另一方面涉及使用结合内皮糖蛋白的人源化和人源化/去免疫化抗体用于检测，诊断或治疗与内皮因子相关的疾病或病症，血管生成或其组合。
-
6.发明申请POTENTIATION OF ANTI-CANCER ACTIVITY THROUGH COMBINATION THERAPY WITH BER PATHWAY INHIBITORS 审中-公开通过与BER路由抑制剂组合治疗的抗癌活动的潜力公开(公告)号：US20130030237A1
公开(公告)日：2013-01-31
申请号：US13640466
申请日：2011-04-15
申请人： Charles Theuer
发明人： Charles Theuer
IPC分类号： A61K31/13 , A61N5/10 , A61K31/4184 , A61P35/00 , A61K31/519 , A61K31/4188
CPC分类号： A61K31/137 , A61K45/06 , A61K2300/00
摘要： Provided herein are pharmaceutical compositions and methods of treating cancer wherein the cytotoxic activity of an anticancer agent is potentiated by the combination of base excision repair (BER) pathway inhibitors.
摘要翻译： 本文提供了治疗癌症的药物组合物和方法，其中抗癌剂的细胞毒性活性通过碱基切除修复（BER）途径抑制剂的组合增强。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.034 秒)
